A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Status:
Not yet recruiting

Trial end date:
2025-10-08

Target enrollment:

Participant gender:

A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy.

Phase 1/Phase 2

Novartis Pharmaceuticals

Azacitidine
Venetoclax